Skip to main content
OpenTrials
Completed

NCT Number: NCT01298609

Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia

The study is designed as a prospective, randomized, double-blind, single center study with a 6 month duration post permanent system implantation. Forty patients will be implanted.

During trial stimulation, patients will be randomized into one of two study arms for two weeks. Crossover will occur at the 2 week study visit to the opposite group. After completion of these two arms, every patient will subsequently complete participation in the third study arm.

After completion of the third arm, patients will be evaluated to determine if they are a positive responder responder. If so, the patient will have the option of obtaining the permanent implant.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Universitair Ziekenhuis Antwerpen

Antwerp, Belgium

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients able to provide informed consent to participate in the study;
  • Patient has had chronic widespread pain for at least 3 months in all 4 body quadrants;
  • Patient has at least 11 out of 18 tender points based on the tender points examination;
  • Patient has attempted "best" medical therapy and has tried and failed at least three documented medically supervised treatments (including, but not limited to drugs, physical therapy, acupuncture, etc.);
  • Patient medication has remained stable for at least 4 weeks prior to baseline data collection;
  • Psychological screening has been completed and the patient has been cleared by a psychologist as a suitable study candidate;
  • Patient agrees not to add or increase medication throughout the randomization trial period of the study;
  • Patient is willing to cooperate with the study requirements including compliance with the treatment regimen and completion of all office visits.

Exclusion criteria

  • Patient has current evidence of any psychiatric disorder, as documented by the DSM-IV-TR criteria with psychotic characteristics, (e.g. bipolar disorder, major depressive disorder);
  • Patient has been diagnosed with any disease mimicking the symptoms of the Fibromyalgia Syndrome (e.g. Epstein Barr, autoimmune diseases, etc.) that is not currently being treated or has not been stable for at least 6 months;
  • Patient is currently in active menopause;
  • Patient has been diagnosed with sleep apnea and is not currently involved in a treatment regime;
  • Patient has a history of substance abuse or substance dependency in the past 6 months prior to baseline data collection;
  • Patient currently participating in another clinical study;
  • Patient with demand-type cardiac pacemakers, an infusion pump or any implantable neurostimulator device;
  • Patient is likely to require an MRI evaluation in the future;
  • Patient is not willing to maintain current medication regimen;
  • Female candidates of child bearing potential who are pregnant (confirmed by positive urine/blood pregnancy test), not using adequate contraception as determined by the investigator, or nursing (lactating) a child.

Treatment and study plan

Occipital Stimulation

Device

Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system

Primary outcomes

  1. Fibromyalgia Impact Questionnaire (FIQ)

    Time frame: End of 6 week stimulation trial

    The Fibromyalgia Impact Questionnaire (FIQ) is a self administered scale that was developed to measure fibromyalgia patient status, progress and outcomes. It measures the components of health that are most affected by fibromyalgia. The maximum score is 100 and a higher score indicates a greater impact of the syndrome on the person.

    The change in the Fibromyalgia Impact Questionnaire (FIQ) will be analyzed and reported.

Sponsors and collaborators

Lead sponsor

Abbott Medical Devices

Industry

Registry information

Official study title

A Randomized Controlled Pilot Study to Examine the Efficacy of Greater Occipital Nerve (C2) Stimulation in the Treatment of Fibromyalgia

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Feb 17, 2011
Registry last updated
Jan 30, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.